Ignite Creation Date:
2025-12-24 @ 4:11 PM
Ignite Modification Date:
2026-01-29 @ 7:38 PM
Study NCT ID:
NCT04965766
Status:
RECRUITING
Last Update Posted:
2025-12-23
First Post:
2021-06-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Metastatic breast cancer | View |
| None | Advanced breast cancer | View |
| None | Unresectable breast cancer | View |
| None | HER2- Breast Cancer | View |
| None | Hormone-receptor positive breast cancer | View |
| None | HR+ breast cancer | View |
| None | Antibody drug conjugate | View |
| None | ADC | View |
| None | Patritumab deruxtecan | View |
| None | U3-1402 | View |
| None | Refractory metastatic breast cancer | View |
| None | HER2 Negative | View |
| None | MBC | View |
| None | ABC | View |
| None | Metastatic BC | View |
| None | Advanced BC | View |
| None | Unresectable BC | View |
| None | Refractory advanced breast cancer | View |
| None | Refractory ABC | View |
| None | Refractory MBC | View |
| None | HER3-DXd | View |
| None | estrogen receptor positive | View |
| None | progesterone receptor positive | View |
| None | ER+ | View |
| None | PR+ | View |
| None | ER+/PR+ | View |